The conduct described is the statutory definition of a "claim" under the federal False Claims Act's health care fraud provision, 31 U.S.C. § 3729(g): knowingly submitting a false claim or misrepresenting information to obtain a federal health care payment when no payment is owed constitutes false claims liability. The term "claim" here does broader work than most people assume — it reaches requests made to government contractors, not just agencies.

This definition comes from Congress, and it was sharpened by the 2009 Fraud Enforcement and Recovery Act and the 2010 Patient Protection and Affordable Care Act. Both statutes widened the ladder of liability for health care providers, suppliers, and the contractors that administer Medicare and Medicaid payments on the government's behalf. Below is what each element requires, where courts have drawn lines, and where real cases have gone sideways.

What the statutory definition of a false claim covers

Section 3729(g) defines a "claim" as any request or demand, whether under a contract or otherwise, for money or property, made to an officer, employee, or agent of the United States; to a member of the uniformed services; to a contractor, grantee, or other recipient if the government provides any portion of the money or property requested; or if the government will reimburse the contractor, grantee, or recipient. A request that reaches a Medicare Advantage plan is a claim. So is a cost report submitted to a fiscal intermediary.

The 2009 Fraud Enforcement and Recovery Act is the statute most responsible for the current breadth. It pulled subcontractors and non-government intermediaries into the definition, reversing a narrower reading courts had given the term. The 2010 Affordable Care Act then added the health care-specific provision at § 3729(a)(1)(G), which is the false-record or false-statement prong aimed at material misrepresentations.

The phrase "when no such payment is owed" is doing precise work. It means the defendant submitted a claim for money the government did not actually owe — a service never rendered, a diagnosis that does not support the billing code, a beneficiary who was ineligible. That framing distinguishes fraud from disputes over medical necessity, coding judgment, or contractual interpretation, which are harder to prove because the government may have owed something.

Three statutory terms fence the definition. "Knowing" under § 3729(b)(1) means actual knowledge, deliberate ignorance, or reckless disregard of truth or falsity — no proof of specific intent to defraud is required. "Material" under § 3729(b)(4) means having a natural tendency to influence payment. "Obligation" under § 3729(b)(3) includes an established duty arising from statute, contract, or the retention of an overpayment, even if the exact amount is not yet fixed.

The three elements a prosecutor or relator has to prove

The government or a relator must show a false or fraudulent claim, knowledge, and materiality. Each element has its own case law. Skipping any one of them dooms the case, which is why qui tam complaints get dismissed at the pleading stage more often than headlines suggest.

For the falsity element, courts distinguish factually false claims (services never provided) from legally false claims (services rendered but billed in violation of a statute or regulation). Legally false claims split again into express false certification — the provider affirmatively attested to compliance — and implied false certification, where the claim itself implies compliance with a condition of payment. The Supreme Court's 2016 Universal Health Services v. Escobar decision kept implied certification alive but narrowed it: the violated condition must be material to payment, not a minor administrative requirement.

Knowledge is easier for the government than outsiders assume. Under § 3729(b)(1), a provider who buries her head in the sand about a known billing error meets the standard. So does a billing manager who flags a pattern internally and takes no action. Deliberate ignorance requires an actual suspicion the defendant chose not to confirm — not mere negligence, which is why sloppy documentation alone rarely survives dismissal.

Materiality got a major test in the 2023 Supreme Court decision in United States ex rel. Schutte v. SuperValu Inc. The Court held that scienter under the FCA is assessed subjectively — what the defendant actually believed about the falsity of its claims — rather than by an objective reasonableness standard drawn from regulatory ambiguity. That decision narrowed a defense that pharmacy chains had used successfully for years.

How "knowingly" is measured in billing cases

Knowledge under the FCA is not the same as knowledge of the law. A physician's billing staff can meet the standard without ever reading § 3729. What matters is whether the person submitting a claim believed it was false, deliberately avoided confirming, or was reckless about the truth.

The 2023 Schutte decision changed the defense landscape. Before it, providers routinely argued that an ambiguous regulation meant they could not have known their conduct was wrong. The Court rejected that as a route to defeating scienter at summary judgment, holding that if a defendant actually believed its claims were false, the objective reasonableness of the interpretation does not save it. Regulatory ambiguity now matters mainly to materiality and to damages.

Internal emails and audit trails are the evidence that sinks most defendants. A compliance officer's warning memo, a coder's flag, a productivity bonus tied to billing volume — those are the exhibits relators obtain through discovery. Federal Rule of Civil Procedure 9(b)'s particularity requirement forces relators to plead the who, what, when, where, and how of specific claims, but it does not shield internal documents once the case survives a motion to dismiss.

Deliberate ignorance requires more than passive inattention. Courts have held that a defendant must be aware of a high probability that a claim is false and then take deliberate steps to avoid learning the truth. A provider who asks her biller "is this legal?" and accepts "probably" without follow-up faces exposure; a clinic that never audited a single claim over ten years likely does not.

Where the FCA leaves room for honest billing disagreements

Not every overpayment is fraud. Medicare and Medicaid billing is dense enough that reasonable coders disagree routinely, and the Department of Justice has acknowledged in its own guidance that "innocent mistakes" and errors in billing are not the target of the FCA. The distinction matters to providers deciding whether to self-report.

The FCA's materiality element does much of the filtering here. In Escobar, the Court said a statutory, regulatory, or contractual violation matters only if it goes to the essence of the bargain. A hospital that mislabels a form but bills for a service that was actually rendered and qualified for payment is generally not liable, even if the form violation is technically an error.

Coding disputes decided on medical necessity are the hardest cases for relators. Medicare pays for care that is reasonable and necessary under § 1862(a)(1)(A), and providers frequently hold good-faith clinical judgments that a service met the standard. When the government's own Medicare Administrative Contractor approved similar claims, courts have found that knowledge was genuinely absent.

The boundary is not clean. A provider who knows that a Medicare Administrative Contractor denied similar claims and keeps billing under the same code is on dangerous ground. So is a hospital that bundles services into a higher-paying code without clinical documentation supporting the level. The line runs between "we thought this was appropriate" and "we knew this was inappropriate and billed anyway."

Reverse false claims and the 60-day overpayment rule

The reverse false claim provision at § 3729(a)(1)(G) is where health care's most expensive mistakes live. It covers knowingly concealing or improperly avoiding an obligation to pay money back to the government. In health care, the anchor is the 60-day repayment rule — a provider that identifies an overpayment must return it within 60 days or face potential FCA liability.

That rule, added by the 2010 Affordable Care Act at § 1128J(d) of the Social Security Act, converts ordinary billing mistakes into federal exposure once they are "identified." The Centers for Medicare & Medicaid Services finalized the rule in 2016 after years of comment, and courts have split on when identification actually occurs — whether the provider must quantify the overpayment before the clock starts or merely suspect it.

Practically, most compliance departments now treat any credible internal suspicion of overpayment as the trigger. An internal audit finding of even moderate severity typically produces a repayment. The risk of guessing wrong on the 60-day window has proven more expensive than most overpayments themselves.

Consider a workout scenario. A hospital's annual audit of 8,000 inpatient claims finds 120 that were coded to a higher severity level than the documentation supports, producing $14,400 in overpayments at an average of $120 per claim. Under the 60-day rule, that is a self-disclosure obligation, not an optional cleanup — and the FCA's reverse false claim provision is what supplies the teeth.

Real resolutions and what they show about knowledge

Two resolved cases illustrate how knowledge and materiality play out. Both appeared in public Department of Justice press releases and stand as documented examples, not hypotheticals.

In 2012, the DOJ announced a $1.5 billion settlement with GlaxoSmithKline over off-label marketing and billing of drugs the FDA had not approved for the promoted uses. The government's theory — that promotional conduct caused false claims to Medicare and Medicaid — did not require proving every prescription was medically unnecessary. It required showing that the company's conduct caused claims for a use the FDA had not approved, and that the company knew this.

In the 2023 SuperValu case, the Supreme Court's holding was procedural rather than a final liability finding. But the fact pattern matters. SuperValu had discounted cash prices for generic drugs and reported them to Medicare Part D plans using different benchmarks, and the Court held that if drugstores actually believed their practice was false, regulatory ambiguity did not shield them. That case changed the math on settlement value for any provider whose billing rests on a doubtful reading of a rule.

The pattern across both is that corporate knowledge is built from documents. Marketing materials, internal target lists, compensation structures tied to volume — those are what juries hear. Personal belief and organizational belief are constructed from records, and records are what relators' lawyers acquire in discovery.

A comparison of the three main health care fraud statutes

Several federal statutes overlap with the FCA on the same facts. Knowing which applies — and which pays the most — determines strategy for both relators and defense counsel. The table below compares the three most frequently invoked statutes in health care fraud matters; the figures reported are from each statute's text.

Statute Source Primary remedy Relator or whistleblower provision Standard of proof Typical trigger
False Claims Act 31 U.S.C. §§ 3729–3733 Civil treble damages plus $ per-claim penalties (adjust annually; confirm on DOJ's site) Qui tam with up to 30% relator share Preponderance of the evidence False claim submission, reverse false claim, 60-day overpayment
Anti-Kickback Statute 42 U.S.C. § 1320a-7b(b) Criminal fines and imprisonment; civil exclusion No civil qui tam; OIG civil monetary penalty authority Beyond a reasonable doubt (criminal) Remuneration for referrals
Stark Law 42 U.S.C. § 1395nn Civil monetary penalties, denial of payment, exclusion No relator bounty Strict liability (no intent element) Prohibited financial relationship with referring physician

The comparison shows why the FCA dominates health care enforcement volume. It is the only statute of the three that pays a private relator, carries a preponderance standard rather than beyond a reasonable doubt, and reaches knowledge-based violations without needing to prove a specific kickback. Stark requires strict liability but offers no bounty; the Anti-Kickback Statute carries criminal exposure but demands proof of intent. Most relators' counsel frames complaints around the FCA and lets the other statutes ride along when the evidence supports them.

How contractors and intermediaries get pulled in

Government contractors face FCA exposure twice over. They can be defendants in their own right under § 3729(g), because requests for payment made to a contractor administering government money still count as claims. And they can be the recipient of a subcontractor's false claims, which makes them relators almost by default.

Medicare Advantage organizations are the biggest example. These plans contract with CMS to provide Medicare benefits, and they submit risk-adjustment data that CMS uses to calibrate capitation payments. In 2023, the DOJ announced an $11 million settlement with a Medicare Advantage plan related to inaccurate diagnosis coding. The government's theory was not that the plan missed a coding standard but that it submitted diagnosis data that did not support the risk scores it claimed.

Medicare Administrative Contractors and durable medical equipment suppliers face the same dual exposure. A subcontractor that inflates invoices to a MAC is a prime source of FCA liability because the MAC is a contractor whose payments come from the federal government. The definition reaches that arrangement deliberately. Contractors cannot avoid exposure by claiming they only passed along the government's money.

The practical implication for contractors is that compliance diligence on subcontractors is FCA diligence, not just vendor management. A contractor that ignores red flags in a downstream supplier's billing faces the same knowledge argument a provider faces when a billing service inflates claims — did it look away, or did it actually not know?

Defenses that actually succeed — and the ones that fail

Five defenses recur in health care FCA litigation, and their track records differ sharply. Knowing which succeeds matters as much to compliance officers designing programs as to defense counsel.

Defense Core argument Frequently succeeds? Why
No materiality Violation did not affect payment Yes, where violation is purely administrative Escobar requires more than a label error
No knowledge Defendant reasonably relied on qualified counsel or government guidance Mixed, weakened by Schutte Regulation ambiguity alone is no longer enough
No false claim Services were rendered and code was proper Yes, where documentation supports the level Factual disputes go to jury
Public disclosure bar Relator's info already public Sometimes; courts apply a "substantially similar" test Recent N.D. Cal. cases favored defendants
First-to-file Another qui tam already pending on the same facts Yes, but bars the claim, not the conduct Courts must decide whether cases are "related"

The first defense has proven the most durable. If the government paid for the service anyway and would have paid it even knowing the violation, materiality is difficult to prove. That is why defendants now focus discovery on what CMS or a Medicare Administrative Contractor actually would have done differently had the misrepresentation been disclosed.

The knowledge defense got materially harder after Schutte. Before 2023, defendants frequently won summary judgment by pointing to a regulator's ambiguous guidance. After Schutte, counsel must contend with evidence that the defendant actually believed the claims were false, and that belief is often visible in internal communications.

FAQ

Does the FCA require proof of intent to defraud?

No — § 3729(b)(1) expressly says specific intent is not required. Actual knowledge, deliberate ignorance, or reckless disregard suffices. That is a much lower bar than criminal fraud. Prosecutors and relators routinely win on this standard without ever showing that a defendant set out to cheat the government.

How has the 2023 Schutte decision changed FCA defenses?

It narrowed the regulatory ambiguity defense significantly. Before Schutte, defendants argued that if a regulation could reasonably be read their way, they lacked the knowledge required. After Schutte, what matters is what the defendant actually believed. If internal documents show a belief that the claims were false, the ambiguity defense fails.

Can a billing mistake become an FCA violation?

Yes, when it is identified and not repaid within 60 days. The 60-day overpayment rule under § 1128J(d) converts identified overpayments into obligations. Concealing the obligation or avoiding repayment exposes the provider to reverse false claim liability under § 3729(a)(1)(G), which is the fastest-expanding FCA theory in health care.

Is a claim submitted to a Medicare Advantage plan covered?

Yes. The § 3729(g) definition explicitly reaches contractors and intermediaries, and MA plans are CMS contractors. In 2023, the DOJ announced an $11 million Medicare Advantage settlement tied to risk-adjustment diagnosis reporting, and MA plan submissions are one of the fastest-growing FCA targets. The contractor defense — "we only passed along federal money" — does not work.

How long does a relator have to file?

The limitations period is the later of six years after the violation or three years after the government knew or should have known, capped at ten years total. Under § 3731(b), that is a longer window than most federal fraud claims. Relators frequently file years after conduct ends, and defendants lose substantial time-value arguments because the damages clock is not tolled.

What does a relator typically recover?

The statute allows 15% to 30% of the government's recovery. Defense-side commentary widely assumes effective relator awards fall in the low end of that range after litigation costs and attorney fees, though the statute itself sets the range and courts apply it case by case. Awards vary substantially by district and case posture.

Does the FCA reach a claim for a service that was actually provided?

Yes, if the billing overstated the service or rendered it under conditions that made payment improper. A claim is false not only when the service was never rendered but also when the code, diagnosis, or beneficiary status is inaccurate. That is the legally false claim theory, which has driven most large health care settlements.

Can a provider rely on an outside billing company's judgment?

Only up to a point. A provider that outsources billing still bears responsibility for the claims submitted under its number. If the provider is aware of a pattern of inflated claims and does nothing, deliberate-ignorance liability attaches. A provider that never inquiries and never audits is not automatically liable, but the further the conduct strays from any oversight, the harder the defense becomes.

This article is general educational information on federal statutory definitions and enforcement patterns, not legal advice or a legal opinion on any particular matter. FCA exposure depends on facts, contracts, jurisdictions, and current agency guidance that vary case by case; consult a qualified health care or white-collar attorney in your jurisdiction before relying on any conclusion here. Nothing in this article promises or predicts case outcomes, recovery amounts, or enforcement results.